because ketoconazole has in-vitro activity against blastomyces dermatitidis , we administered this agent in a dosage of 400 mg/d to 46 patients with blastomycosis , with 43 patients receiving at least 1 month of therapy .
C0022625
ketoconazole
C0005716
blastomycosis